Peptide Calculator

CJC-1295 & Ipamorelin Dosage Calculator

Calculate CJC-1295 + Ipamorelin stack reconstitution, GHRH/GHRP secretagogue math, and syringe units.

CJC-1295 & Ipamorelin Pre-filled Reconstitution Tool

Pre-loaded with common CJC-1295 & Ipamorelin vial size and reconstitution ratios.

U-100 Syringe Standard
Total compound mass
mg
Added diluent
mL
mcg
Standard U-100
Calculation OutputU-100 Calibrated
Draw Exactly To:
10.0Units
Line 10 on your syringe (0.10 mL volume)
Concentration
2.50 mg/mL
Doses per Vial
20 Doses
Visual Syringe Indicator1.0 mL Syringe

Reconstitution Summary Card

Stored locally on your device (No account needed)

Author:Rohit Nimbalkar
Last updated:
Sources checked: 2026-11-10
Editorial PolicyReport Error

📌At a Glance: CJC-1295 & Ipamorelin Reconstitution Arithmetic

  • Dual-Component Formulation: Combines a synthetic GHRH analogue (Sermorelin-related tetrasubstituted peptide) with a selective ghrelin-receptor/GHRP agonist (Ipamorelin).
  • Critical Math Rule: In co-lyophilized blend vials, calculate syringe draw units based on each individual peptide mass, never by summing them into an ambiguous total.
  • Related Growth Peptides: Compare with Tesamorelin (44-amino-acid GHRH) and AOD-9604 (GH fragment).
  • Syringe Scale: Calibrated strictly on standard U-100 insulin syringes (100 units = 1.0 mL).
⚖️Regulatory & Compound Status
Verified: 2026-11-10

Neither CJC-1295 nor Ipamorelin is an FDA-approved drug product. In September 2023, the FDA classified CJC-1295 and Ipamorelin under Category 2 of the 503A Bulk Drug Substances list due to significant safety concerns regarding potential systemic adverse events from sustained growth hormone elevation. Both substances are prohibited under WADA Section S2 (Peptide Hormones, Growth Factors, and Related Substances).

Official Sources:Safety Risks Associated with Certain Bulk Drug Substances Nominated for 503A/503B Compounding,World Anti-Doping Code International Standard: Prohibited List (S2: Peptide Hormones),Prolonged Stimulation of Growth Hormone and IGF-I Secretion by CJC-1295 in Healthy Adults
ℹ️What This Tool Cannot Tell You
  • A therapeutic prescription, cycling schedule, or clinical human dosing recommendation.
  • The physiological amplitude or duration of endogenous growth hormone pulses in individual test subjects.
  • How to separate or independently adjust the ratio of CJC-1295 and Ipamorelin once co-lyophilized in the same vial.
  • Whether compounding of these unapproved peptide bulk drug substances complies with current FDA 503A or state regulatory mandates.

This tool converts volumetric liquid measurements and syringe tick marks only. It does not provide medical guidance, dosing schedules, or clinical administration protocols. Review our Medical & Research Disclaimer.

What Is CJC-1295 & Ipamorelin?

CJC-1295 & Ipamorelin (often abbreviated simply as CJC or CJC 1295 ipamorelin) is a dual growth hormone secretagogue combination blending a Growth Hormone-Releasing Hormone (GHRH) analogue with a selective Growth Hormone Secretagogue Receptor (GHSR) agonist. CJC-1295 (typically Mod GRF 1-29 without DAC) binds to pituitary GHRH receptors, while Ipamorelin selectively targets ghrelin receptors.

Co-administering GHRH and GHRP compounds produces a coordinated pulse of endogenous growth hormone in experimental models without significantly elevating cortisol, prolactin, or aldosterone. Researchers comparing GH secretagogues also evaluate Sermorelin and Tesamorelin. Reconstituting CJC-1295 & Ipamorelin blend vials using our peptide calculator and bacteriostatic water guarantees exact microgram accuracy.

CJC-1295 & Ipamorelin Dosage Chart

A standard 5 mg blend vial contains 2 mg CJC-1295 (Mod GRF 1-29) and 3 mg Ipamorelin (2:3 mass ratio). Reconstituting with 2.0 mL of bacteriostatic water yields 1,000 mcg/mL CJC-1295 and 1,500 mcg/mL Ipamorelin. A 10 unit draw delivers 100 mcg CJC-1295 and 150 mcg Ipamorelin.

Vial SizeBac Water AddedConcentrationExample AmountDraw Units (U-100)
5 mg Total (2/3)2.0 mL1.0 / 1.5 mg/mL100 mcg CJC / 150 mcg Ipam10.0 Units
5 mg Total (2/3)2.5 mL0.8 / 1.2 mg/mL100 mcg CJC / 150 mcg Ipam12.5 Units
10 mg Total (5/5)2.0 mL2.5 / 2.5 mg/mL100 mcg CJC / 100 mcg Ipam4.0 Units
10 mg Total (5/5)5.0 mL1.0 / 1.0 mg/mL100 mcg CJC / 100 mcg Ipam10.0 Units

Dual-Peptide Blend Reconstitution Reference Matrix

The table below calibrates per-component concentrations and syringe draw units across standard blend vial configurations. For related single-compound GHRH secretagogues and fragment analogues, see our Sermorelin calculator, Tesamorelin calculator, and AOD-9604 calculator. For step-by-step volumetric math derivations, see our guide on how to calculate peptide dosage.

Vial CompositionBac Water AddedCJC-1295 Conc.Ipamorelin Conc.Resolution (per U-100 mark)Draw for 100/100 mcg Target
2 mg + 3 mg (5 mg)2.0 mL1.0 mg/mL (1,000 mcg/mL)1.5 mg/mL (1,500 mcg/mL)10 mcg CJC / 15 mcg Ipam10 units (100 mcg CJC / 150 mcg Ipam)
2 mg + 3 mg (5 mg)2.5 mL0.8 mg/mL (800 mcg/mL)1.2 mg/mL (1,200 mcg/mL)8 mcg CJC / 12 mcg Ipam12.5 units (100 mcg CJC / 150 mcg Ipam)
5 mg + 5 mg (10 mg)2.0 mL2.5 mg/mL (2,500 mcg/mL)2.5 mg/mL (2,500 mcg/mL)25 mcg CJC / 25 mcg Ipam4 units (0.04 mL)
5 mg + 5 mg (10 mg)2.5 mL2.0 mg/mL (2,000 mcg/mL)2.0 mg/mL (2,000 mcg/mL)20 mcg CJC / 20 mcg Ipam5 units (0.05 mL)
5 mg + 5 mg (10 mg)5.0 mL1.0 mg/mL (1,000 mcg/mL)1.0 mg/mL (1,000 mcg/mL)10 mcg CJC / 10 mcg Ipam10 units (0.10 mL)

Worked Arithmetic for Dual-Peptide Blend: 5 mg + 5 mg in 2.0 mL

Example Parameters:
  • Blend vial composition: 5 mg CJC-1295 + 5 mg Ipamorelin (10 mg total combined mass)
  • Reconstitution diluent volume: 2.0 mL bacteriostatic water
  • Illustrative target quantity: 500 mcg (0.50 mg) of each component
  • Syringe standard: U-100 insulin syringe (100 units = 1.0 mL = 0.01 mL per unit)
Step-by-Step Calculation:
  1. Determine component concentration: 5 mg CJC-1295 ÷ 2.0 mL = 2.5 mg/mL (2,500 mcg/mL) CJC-1295, and 5 mg Ipamorelin ÷ 2.0 mL = 2.5 mg/mL (2,500 mcg/mL) Ipamorelin.
  2. Calculate unit resolution per component: 2,500 mcg/mL ÷ 100 units/mL = 25 mcg per U-100 unit mark for each peptide.
  3. Calculate liquid draw volume for 500 mcg target: 500 mcg ÷ 2,500 mcg/mL = 0.20 mL.
  4. Convert liquid volume to syringe markings: 0.20 mL × 100 units/mL = 20 units on a U-100 syringe barrel.
  5. Deterministic back-check: 20 units × 25 mcg/unit = 500 mcg (0.50 mg) of CJC-1295 and 20 units × 25 mcg/unit = 500 mcg (0.50 mg) of Ipamorelin. Volume check: 0.20 mL × 2.5 mg/mL = 0.50 mg each, confirming arithmetic precision.
Result:

Draw 20 units (0.20 mL) on a standard U-100 insulin syringe to deliver 500 mcg of CJC-1295 and 500 mcg of Ipamorelin simultaneously.

Note: Arithmetic verification: 20 units delivers exactly 0.50 mg (500 mcg) of each compound simultaneously. A 20-unit volume fits with high volumetric precision in a 0.3 mL (30-unit) or 0.5 mL (50-unit) syringe.

Common Calculation & Measurement Mistakes

⚠️The Total-Mass Blending Error

A 5 mg + 5 mg blend vial contains 10 mg of total dry powder. If a researcher calculates concentration using the 10 mg total (10 mg ÷ 2 mL = 5 mg/mL) instead of individual component masses (2.5 mg/mL each), all resulting syringe draw calculations will deliver only half the expected microgram amount of each peptide.

⚠️Confusing CJC-1295 'With DAC' and 'Without DAC' (Mod GRF 1-29)

CJC-1295 with Drug Affinity Complex (DAC) contains a maleimidoproprionic acid group that forms covalent bonds with circulating serum albumin, extending circulating half-life to 6–8 days (PMID 16822820). In contrast, modified GRF 1-29 ('CJC-1295 without DAC') lacks this moiety and possesses a brief half-life (~30 minutes), mimicking endogenous pulsatile secretion.

⚠️Syringe Type Confusion (U-100 vs U-40)

All conversions on this tool assume standard U-100 insulin syringes (100 units = 1.0 mL). Using a veterinary U-40 syringe (40 units = 1.0 mL) causes a 2.5-fold volumetric error (a 20-unit mark on a U-40 syringe delivers 0.50 mL, or 125 units of U-100 volume).

How to Reconstitute CJC-1295 & Ipamorelin

Reconstituting CJC-1295 & Ipamorelin requires gentle diluent introduction to prevent protein shearing of delicate peptide bonds.

Visual Standard Operating Procedure

CJC-1295 & Ipamorelin Step-by-Step SOP

1. Sanitize70% Isopropyl swabon vial stoppers2. Draw WaterBacteriostatic waterusing mixing syringe3. Glass WallAim slow streamagainst glass wall4. Swirl GentlyNever shake vialSwirl until clear5. Cold StorageRefrigerate 2°C–8°CProtect from light

5 Standard Reconstitution Steps for CJC-1295 & Ipamorelin

  1. Clean the rubber stoppers of both the blend vial and bacteriostatic water vial with 70% isopropyl alcohol prep pads.
  2. Draw 2.0 mL of sterile bacteriostatic water into a sterile mixing syringe.
  3. Inject water slowly against the internal glass wall of the blend vial.
  4. Swirl the vial gently until the white powder dissolves into a crystal-clear liquid.
  5. Store reconstituted vial in a refrigerator at 2°C–8°C.

❄️ Storage & Shelf-Life Notice (CJC-1295 & Ipamorelin)

Store reconstituted multi-dose vials refrigerated at 2°C–8°C (36°F–46°F) and never freeze. Under FDA multi-dose sterile vial guidance, discard opened multi-dose vials within 28 days of first puncture.

⚠️ Common Preparation Mistakes to Avoid

Confusing CJC-1295 No DAC (Mod GRF 1-29, half-life ~30 minutes) with CJC-1295 DAC (Drug Affinity Complex, half-life 6-8 days), shaking the vial, and freezing reconstituted liquid.

CJC-1295 & Ipamorelin Dosing FAQ

What is the difference between CJC-1295 DAC and CJC-1295 No DAC?↓
CJC-1295 DAC contains a Drug Affinity Complex affinity tag that binds to albumin extending half-life to 6-8 days. CJC-1295 No DAC (Mod GRF 1-29) lacks DAC, having a 30-minute half-life ideal for natural pulsatile GH release.
How much bac water do I add to a 5mg CJC-1295 / Ipamorelin blend vial?↓
Adding 2.0 mL of bac water to a 5 mg blend vial (2mg CJC / 3mg Ipam) allows a 10 unit draw on a U-100 syringe to yield 100 mcg CJC-1295 and 150 mcg Ipamorelin.
How are syringe units calculated for a combined CJC-1295 and Ipamorelin vial?↓
Divide each component's labeled milligram mass by the total diluent volume separately to get its individual concentration (mg/mL). A single syringe draw delivers both compounds in proportion to their labeled masses.
Does Ipamorelin increase appetite or prolactin?↓
Unlike older GHRPs like GHRP-6 or GHRP-2, Ipamorelin is selective for GHSR in published pharmacology studies, without the same cortisol or prolactin stimulation profile.
Can I use this calculator for a single-agent CJC-1295 or Ipamorelin vial?↓
Use the main calculator in Single mode on the home page for a single-peptide vial, or enter zero for the second component when calculating single-vial concentrations.

Related Peptide Calculators & Stacks

AOD-9604
Calculate reconstitution volume, solution concentration, and U-100 syringe units for research AOD-9604 vials.
Calculate AOD-9604→
Sermorelin
Calculate Sermorelin GHRH analogue reconstitution, microgram dosing, and U-100 syringe units.
Calculate Sermorelin→
Tesamorelin
Calculate reconstitution volume, solution concentration, and U-100 syringe units for tesamorelin vials.
Calculate Tesamorelin→

Related Reconstitution & Dosing Guides

View All FAQs→
General Peptide FAQ
How to Reconstitute Peptides?
→
General Peptide FAQ
What Size Needle to Reconstitute Peptides?
→
General Peptide FAQ
What to Reconstitute Peptides With?
→

Scientific & Regulatory References

View Full Sources Registry→

The mathematical formulas on this page are deterministic volumetric conversions. Non-mathematical parameters, regulatory status notes, and chemical safety guidelines are referenced directly to the primary sources cataloged below:

  1. [1]
    Safety Risks Associated with Certain Bulk Drug Substances Nominated for 503A/503B Compounding
    U.S. Food and Drug Administration•Type: fda communication•Verified: 2026-10-20

    FDA Category 2 classification covering safety considerations for BPC-157, AOD-9604, and CJC-1295.

  2. [2]
    World Anti-Doping Code International Standard: Prohibited List (S2: Peptide Hormones)
    World Anti-Doping Agency (WADA)•Type: regulatory list•Verified: 2026-10-20

    Prohibits growth hormone secretagogues (GHS), GH fragments, BPC-157, TB-500, and metabolic modulators.

  3. [3]
    Prolonged Stimulation of Growth Hormone and IGF-I Secretion by CJC-1295 in Healthy Adults
    Journal of Clinical Endocrinology & Metabolism (PubMed PMID: 16822820)•Type: peer reviewed•Verified: 2026-10-20

    Pharmacokinetic and pharmacodynamic characterization of tetra-substituted GHRH 1-29 analogue with DAC.

  4. [4]
    Bacteriostatic Water for Injection, USP Multi-Dose Prescribing Details
    U.S. National Library of Medicine (DailyMed / Hospira / Pfizer)•Type: fda label•Verified: 2026-10-20

    Sterile multi-dose diluent specification containing 0.9% (9 mg/mL) benzyl alcohol preservative.

  5. [5]
    FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
    U.S. Food and Drug Administration (FDA CDER)•Type: fda communication•Verified: 2026-11-08

    FDA safety alert detailing risks of unapproved compounded GLP-1 drugs, dosing errors, lack of pre-market review, improper cold-chain shipping temperatures, and recommendation to discard multi-dose sterile vials 28 days after first puncture.

  6. [6]
    USP General Chapter <797>: Pharmaceutical Compounding — Sterile Preparations
    United States Pharmacopeial Convention (USP)•Type: standard•Verified: 2026-10-20

    Standards for beyond-use dates (BUD), refrigeration controls (2°C–8°C), and multi-dose sterility.

  7. [7]
    Embecta Ultra-Fine™ U-100 Insulin Syringe Product Specifications
    embecta (formerly BD Diabetes Care)•Type: manufacturer spec•Verified: 2026-11-08

    Manufacturer specifications for sterile single-use U-100 insulin syringes (0.3 mL, 0.5 mL, and 1.0 mL capacities with 1-unit and 1/2-unit scales).